96 related articles for article (PubMed ID: 20607679)
1. KRAS testing on colo-rectal carcinoma cytological imprints.
Malapelle U; Bellevicine C; Russo A; Salatiello M; Palombini L; Troncone G
Diagn Cytopathol; 2011 Apr; 39(4):274-7. PubMed ID: 20607679
[TBL] [Abstract][Full Text] [Related]
2. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
5. Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Chang SC; Denne J; Zhao L; Horak C; Green G; Khambata-Ford S; Bray C; Celik I; Van Cutsem E; Harbison C
Clin Colorectal Cancer; 2013 Sep; 12(3):195-203.e2. PubMed ID: 23978462
[TBL] [Abstract][Full Text] [Related]
6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
7. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
8. [KRAS mutation test].
Hinoda Y
Rinsho Byori; 2011 Jun; 59(6):598-601. PubMed ID: 21815483
[TBL] [Abstract][Full Text] [Related]
9. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.
Hoorens A; Jouret-Mourin A; Sempoux C; Demetter P; De Hertogh G; Teugels E
Acta Gastroenterol Belg; 2010; 73(4):497-503. PubMed ID: 21299161
[TBL] [Abstract][Full Text] [Related]
10. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
11. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
[TBL] [Abstract][Full Text] [Related]
13. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
Garassino MC; Farina G; Rossi A; Martelli O; Torri V
J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
[No Abstract] [Full Text] [Related]
14. KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer.
Troncone G; Malapelle U; Cozzolino I; Palombini L
Diagn Cytopathol; 2010 Dec; 38(12):869-73. PubMed ID: 20049979
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy.
Kimura T; Okamoto K; Miyamoto H; Kimura M; Kitamura S; Takenaka H; Muguruma N; Okahisa T; Aoyagi E; Kajimoto M; Tsuji Y; Kogawa T; Tsuji A; Takayama T
Oncology; 2012; 82(5):298-304. PubMed ID: 22555244
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.
Tsoukalas N; Tzovaras AA; Tolia M; Kostakis ID; Papakostidi A; Pistamaltzian N; Ardavanis A
J BUON; 2012; 17(1):73-8. PubMed ID: 22517696
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
18. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
Kim R; Kubal T
Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
[No Abstract] [Full Text] [Related]
19. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
Au HJ; Karapetis CS; O'Callaghan CJ; Tu D; Moore MJ; Zalcberg JR; Kennecke H; Shapiro JD; Koski S; Pavlakis N; Charpentier D; Wyld D; Jefford M; Knight GJ; Magoski NM; Brundage MD; Jonker DJ
J Clin Oncol; 2009 Apr; 27(11):1822-8. PubMed ID: 19273701
[TBL] [Abstract][Full Text] [Related]
20. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Harbison CT; Horak CE; Ledeine JM; Mukhopadhyay P; Malone DP; O'Callaghan C; Jonker DJ; Karapetis CS; Khambata-Ford S; Gustafson N; Trifan OC; Chang SC; Ravetto P; Iv GA
Arch Pathol Lab Med; 2013 Jun; 137(6):820-7. PubMed ID: 23030695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]